| 李凌云,解华,张宁,等.奥沙利铂分别联合卡培他滨和替吉奥治疗晚期结直肠癌的临床疗效分析[J].安徽医药,2016,20(8):1570-1572. |
| 奥沙利铂分别联合卡培他滨和替吉奥治疗晚期结直肠癌的临床疗效分析 |
| Study of capecitabine plus oxaliplatin and tegefur gimeracil plus oxaliplatin in the treatment of patients with advanced colorectal cancer |
| 投稿时间：2016-04-28 |
| DOI： |
| 中文关键词: 结直肠肿瘤 奥沙利铂 卡培他滨 替吉奥 治疗结果 |
| 英文关键词: Colorectal neoplasms Oxaliplatin Capecitabine Gimeracil Treatment outcome |
| 基金项目: |
|
| 摘要点击次数: 2812 |
| 全文下载次数: 170 |
| 中文摘要: |
| 目的 探讨奥沙利铂分别联合卡培他滨和替吉奥两种治疗方案对晚期结直肠癌的临床疗效及不良反应比较,为临床应用提供理论和实践的依据。方法 选取68例符合入组标准的晚期结直肠癌患者,按照用药方案的不同分成卡培他滨联合奥沙利铂治疗组(A组)35例,替吉奥联合奥沙利铂组(B组) 33例,通过观察两组方案的近期疗效、疾病进展时间及不良反应,分析评价两种方案的临床效果。结果 两种方案的近期疗效、疾病进展时间和不良反应发生情况,差异无统计学意义(P>0.05)。结论 卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗晚期结直肠癌疗效相当,不良反应差异无统计学意义,两种方案均可作为晚期结直肠癌患者治疗的较好选择。 |
| 英文摘要: |
| Objective To compare the clinical efficacy and adverse reaction of advanced colorectal cancer treated with capecitabine or tegefur gimeracil combined with oxaliplatin.Methods We selected 68 cases of patients who conform to the standard of the study treated.According to the non-matching principle,35 cases were assigned into capecitabine plus oxaliplatin group and 33 cases in tegefur gimeracil plus oxaliplatin group.The differences in efficacy and adverse reaction between the two groups were compared.The time to progression was also observed.Results The objective response rate,the disease control rate and the median time to progression in capecitabine group and tegefur gimeracil group were 40.0% vs 42.4%,82.9% vs 84.8%,and 12 months vs 13 months.Adverse effects were similar in the two groups,so there were no significant differences between the two groups.Conclusions The effects are the same between therapies of capecitabine or tegefur gimeracil combined with oxaliplatin,and they both could be regarded as options for patients with advanced colorectal cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
